Cognition and NeuroImaging in neuroDegenerative Disorders (CogNID)
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Dementia (Diagnosis)
- Sponsor
- Nottingham University Hospitals NHS Trust
- Enrollment
- 125
- Locations
- 2
- Primary Endpoint
- Neurocognitive scales on Birmingham Cognitive Screen (BCoS) Scores
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
This prospective study aims:
- to compare cognitive performance in different clinical groups of participants with mild cognitive impairment (MCI) or mild dementia [Alzheimer's Disease (AD), Vascular Cognitive Impairment (VCI) and Fronto-temporal Dementia (FTD)] to determine whether scores reveal differential profiles between the groups,
- to demonstrate differences in imaging markers between different dementia syndromes and healthy volunteers using ultra high-field MRI at 7T.
Detailed Description
The imaging arm of the study include: 1. to demonstrate differences in brain iron levels between different dementia syndromes and healthy volunteers using ultra high-field MRI, quantitative susceptibility mapping (QSM) at 7T. 2. to demonstrate variations in the resting oxygen usage as an important biomarker to discriminate between different dementia syndromes. 3. to demonstrate cerebral blood flow changes in the brain, particularly in the hippocampus region, and its correlation with different dementia syndromes using Arterial Spin Labelling MRI technique. 4. to demonstrate increased blood brain barrier leakage in the brain, particularly in the hippocampus region, and its correlation with Alzheimer's Disease (AD) and Vascular Cognitive Impairment (VCI) using a new dynamic contrast-enhanced MRI (DCE-MRI) technique.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Ability to give informed consent.
- •Either pathological, genetic or imaging biomarker evidence to suggest Fronto-temporal Lobar Degeneration, Alzheimer's Disease or Vascular Cognitive Impairment, or defined clinical diagnoses.
Exclusion Criteria
- •Lack of mental capacity to consent to study involvement.
- •Not speaking English before age 5 years.
- •Learning disability.
- •MRI contraindications
Outcomes
Primary Outcomes
Neurocognitive scales on Birmingham Cognitive Screen (BCoS) Scores
Time Frame: Through study completion (an average of one year)
cognitive sub scores in relation to clinical phenotype
Secondary Outcomes
- Structural imaging changes on MRI at 3T(Through study completion (an average of one year))
- Susceptibility weighted mapping at 7T(Through study completion (an average of one year))